CD8A and neoplasm: A study in patients treated with RFA or TACE showed that tumor-associated antigens (glypican-3, NY-ESO-1, and MAGE-1)-specific CD8+ T cell responses suppress the recurrence of HCC, and that c-TACE-induced tumor-specific response [38].